Cargando…
Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner
Tenofovir (TFV) is used in combination with other antiretroviral drugs for human immunodeficiency virus (HIV) treatment and prevention. TFV requires two phosphorylation steps to become pharmacologically active; however, the kinases that activate TFV in cells and tissues susceptible to HIV infection...
Autores principales: | Lade, Julie M., To, Elaine E., Hendrix, Craig W., Bumpus, Namandjé N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588390/ https://www.ncbi.nlm.nih.gov/pubmed/26501112 http://dx.doi.org/10.1016/j.ebiom.2015.07.008 |
Ejemplares similares
-
Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067
por: Figueroa, Dominique B., et al.
Publicado: (2018) -
A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate
por: Yang, Kuo-Hsiung, et al.
Publicado: (2014) -
Tenofovir Activation is Diminished in the Brain and Liver of Creatine Kinase Brain-Type Knockout Mice
por: Eberhard, Colten D., et al.
Publicado: (2023) -
A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention
por: Jayachandran, Priya, et al.
Publicado: (2021) -
MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments
por: Hendrix, Craig W., et al.
Publicado: (2013)